ๆญฃๅœจๅŠ ่ฝฝ่ง†้ข‘...

่ง†้ข‘ๅŠ ่ฝฝๅคฑ่ดฅ

่ฟ”ๅ›ž้ฆ–้กต

๐…๐ซ๐จ๐ฆ ๐ญ๐ก๐ž ๐๐š๐ฒ ๐€๐ซ๐ž๐š: Gordian Biotechnology announced that it will be using its unique large-scale in vivo screening process to help Pfizer look for new targets against obesity. Co Founder & CSO Martin Borch Jensen explains how it works. Full video:

BiotechTV's profile picture

BiotechTV

11,475 subscribers

13,213 ๆฌก่ง‚็œ‹ โ€ข 6 ไธชๆœˆๅ‰ โ€ขvia X (Twitter)

LIVE

Anya Rossiโ€ข Live Now

Private livecam show

0 ๆก่ฏ„่ฎบ

ๆš‚ๆ— ่ฏ„่ฎบ

ๅŽŸๅง‹ๅธ–ๅญ็š„่ฏ„่ฎบๅฐ†ๆ˜พ็คบๅœจ่ฟ™้‡Œ

็›ธๅ…ณ่ง†้ข‘

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:
3:45

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: ArsenalBio Co-Founder & CEO ken drazan talks about engineering the next generation of T-cell therapies, including a clinical stage renal cell program that includes multiple features. Full video:

BiotechTV

11,057 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:
4:58

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: AstraZeneca's CEO Pascal Soriot shares his take on M&A, oncology, Baxfendy for hypertension, the obesity market, and more. $AZN Full video:

BiotechTV

36,428 ๆฌก่ง‚็œ‹ โ€ข 2 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:
5:19

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: After switching to a new GalNAc-LNP delivery vehicle a year ago, @VerveTx today announced the initial safety and efficacy data from its VERVE-102 PCSK9 based editor. Co-Founder & CEO Sek Kathiresan MD covers the data. $VERV Full video:

BiotechTV

22,484 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: KeloniaTx presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation. Full video:
4:43

๐€๐’๐‡ ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ“: KeloniaTx presented convincing late-breaking data at ASH today from its initial patients in multiple myeloma suggesting that in vivo CAR-T is on track to be a next innovation. Full video:

BiotechTV

21,941 ๆฌก่ง‚็œ‹ โ€ข 8 ไธชๆœˆๅ‰

๐…๐ซ๐จ๐ฆ ๐’๐ž๐จ๐ฎ๐ฅ: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:
4:12

๐…๐ซ๐จ๐ฆ ๐’๐ž๐จ๐ฎ๐ฅ: Daejeon based Orum Therapeutics is pioneering the field of degrader-antibody conjugates. Founder SJ Lee describes the science and gives us an overview of biotech in Korea. Full video:

BiotechTV

15,588 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

๐„๐ฉ๐ข๐ ๐ž๐ง๐ž๐ญ๐ข๐œ๐ฌ: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder & President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.
3:01

๐„๐ฉ๐ข๐ ๐ž๐ง๐ž๐ญ๐ข๐œ๐ฌ: BiotechTV visited NewLimit in South San Francisco and heard from Co-Founder & President Jacob Kimmel how they are trying to tackle diseases of aging through epigenetic reprogramming.

BiotechTV

85,263 ๆฌก่ง‚็œ‹ โ€ข 6 ไธชๆœˆๅ‰

๐€๐’๐‚๐Ž ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-ฮฒ with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:
1:56

๐€๐’๐‚๐Ž ๐Ÿ๐ŸŽ๐Ÿ๐Ÿ”: Bicara Therapeutics is presenting long-term follow up data at ASCO that it believes shows durability derived from choosing TGF-ฮฒ with EGFR for its fusion protein in HPV negative head & neck. $BCAX #ASCO26 Full video:

BiotechTV

11,479 ๆฌก่ง‚็œ‹ โ€ข 2 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:
3:01

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Abivax CEO Marc de Garidel discusses freshly released maintenance part 2 results for obefazimod in UC and describes how he believes it builds on initial data announced earlier this month. $ABVX Watch the full video:

BiotechTV

22,305 ๆฌก่ง‚็œ‹ โ€ข 1 ไธชๆœˆๅ‰

When facing attacks by multiple drones, forces have to act quickly. They have just seconds to make an โ€œoptimalโ€ decision, in the toughest of circumstances. But what if that decision could be made easier, with the help of AI? Thatโ€™s the question Anduril Industries is tackling in a new partnership with OpenAI. Brian Schimpf, the CEO and co-founder of Anduril, explains how it works with a16z Growthโ€™s David George.
0:52

When facing attacks by multiple drones, forces have to act quickly. They have just seconds to make an โ€œoptimalโ€ decision, in the toughest of circumstances. But what if that decision could be made easier, with the help of AI? Thatโ€™s the question Anduril Industries is tackling in a new partnership with OpenAI. Brian Schimpf, the CEO and co-founder of Anduril, explains how it works with a16z Growthโ€™s David George.

a16z

67,968 ๆฌก่ง‚็œ‹ โ€ข 1 ๅนดๅ‰

Anthropic co-founder Chris Olah: There is a real possibility that AI will displace human labor at a very large scale. If that happens, supporting those displaced will be a moral imperative of historic proportions. AI development is concentrated in a handful of wealthy nations. How will we ensure that the gains of AI are shared globally? We do not have a mechanism for this. It is an unsolved problem.
0:30

Anthropic co-founder Chris Olah: There is a real possibility that AI will displace human labor at a very large scale. If that happens, supporting those displaced will be a moral imperative of historic proportions. AI development is concentrated in a handful of wealthy nations. How will we ensure that the gains of AI are shared globally? We do not have a mechanism for this. It is an unsolved problem.

Clash Report

79,907 ๆฌก่ง‚็œ‹ โ€ข 2 ไธชๆœˆๅ‰

Peskov has outdone himself in cynicism โ€œYou know that at the moment the peace process is on pause. We expect that it will eventually be resumed. As for the strikes by our armed forces, they are carried out only against military or quasi-military targets. In this regard, it is also worth once again paying attention to the ongoing strikes by the armed forces of Ukraine using drones against civilian targets and civilian infrastructure in various Russian cities and settlements,โ€ he said.
0:37

Peskov has outdone himself in cynicism โ€œYou know that at the moment the peace process is on pause. We expect that it will eventually be resumed. As for the strikes by our armed forces, they are carried out only against military or quasi-military targets. In this regard, it is also worth once again paying attention to the ongoing strikes by the armed forces of Ukraine using drones against civilian targets and civilian infrastructure in various Russian cities and settlements,โ€ he said.

NEXTA

54,659 ๆฌก่ง‚็œ‹ โ€ข 3 ไธชๆœˆๅ‰

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:
4:35

๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ฒ ๐๐ž๐ฐ๐ฌ: Aerska launched in the UK today with $21M in financing to develop RNAi medicines for neurological conditions that are delivered to the brain via 'brain shuttle' technologies. CEO Jack O'Meara explains. Full video:

BiotechTV

19,198 ๆฌก่ง‚็œ‹ โ€ข 10 ไธชๆœˆๅ‰

CAR-T for Glioblastoma: Penn Medicine's Dr. Donald O'Rourke describes advances being seen today in using CAR-T against glioblastoma. Penn Medicine - Abramson Cancer Center Full video:
1:23

CAR-T for Glioblastoma: Penn Medicine's Dr. Donald O'Rourke describes advances being seen today in using CAR-T against glioblastoma. Penn Medicine - Abramson Cancer Center Full video:

BiotechTV

17,518 ๆฌก่ง‚็œ‹ โ€ข 2 ๅนดๅ‰

๐๐ซ๐ž๐š๐ค๐ข๐ง๐  ๐Œ&๐€ ๐๐ž๐ฐ๐ฌ: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.
4:50

๐๐ซ๐ž๐š๐ค๐ข๐ง๐  ๐Œ&๐€ ๐๐ž๐ฐ๐ฌ: Lilly is acquiring Crossbridgebio, a Texas biotech developing dual payload antibody-drug conjugates, for up to $300M. Co-Founder & CEO Michael Torres tells us.

BiotechTV

20,285 ๆฌก่ง‚็œ‹ โ€ข 4 ไธชๆœˆๅ‰

๐€๐ˆ ๐๐ž๐ฐ๐ฌ: Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today. Full video:
3:11

๐€๐ˆ ๐๐ž๐ฐ๐ฌ: Bay Area based Medra, which is building a robotics platform that is capable of doing fully automated lab work for drug discovery and then analyzing and optimizing it, announced a $52M series A today. Full video:

BiotechTV

15,086 ๆฌก่ง‚็œ‹ โ€ข 8 ไธชๆœˆๅ‰

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: Mizuho Senior Analyst Graig Suvannavejh shares his take on biotech and companies he covers that are in the news with key catalysts. $TERN $CRVS $INSM $CRBP $AXSM $NMRA $EYPT $AMLX Full video:
4:48

๐…๐ซ๐จ๐ฆ ๐๐˜๐’๐„: Mizuho Senior Analyst Graig Suvannavejh shares his take on biotech and companies he covers that are in the news with key catalysts. $TERN $CRVS $INSM $CRBP $AXSM $NMRA $EYPT $AMLX Full video:

BiotechTV

17,128 ๆฌก่ง‚็œ‹ โ€ข 8 ไธชๆœˆๅ‰

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset. $OLEM Full video:
4:00

๐‰๐ž๐Ÿ๐Ÿ๐ž๐ซ๐ข๐ž๐ฌ ๐‹๐จ๐ง๐๐จ๐ง: Olema Oncology more than doubled yesterday when Roche announced surprise data for its oral SERD - the CEO reacts and shares the development program for Olema's competing asset. $OLEM Full video:

BiotechTV

12,936 ๆฌก่ง‚็œ‹ โ€ข 9 ไธชๆœˆๅ‰